Table 3 Frequency of rituximab response according to myositis type, clinical involvement, autoantibody profile and treatment
From: Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies
Responders (N = 29) | Non-responders (N = 9) | P | |
|---|---|---|---|
Age at disease diagnosis (years) | 39.6 ± 12.2 | 28.3 ± 9.0 | 0.008 |
Age at Rituximab application (years) | 44.7 ± 11.0 | 35.8 ± 8.1 | 0.017 |
Female gender | 24 (82.7) | 8 (88.9) | 1.000 |
White ethnicity | 19 (65.5) | 7 (77.8) | 0.689 |
Disease duration (years) | 3.0 (1.5–5.5) | 3.0 (2.0–10.0) | 0.919 |
Duration: diagnosis - symptoms (months) | 5.0 (3.0–8.0) | 4.0 (2.5–12.0) | 0.589 |
Myositis | |||
Dermatomyositis | 14 (48.3) | 1 (11.2) | 0.061 |
Polymyositis | 6 (20.7) | 4 (44.4) | 0.205 |
Antisynthetase syndrome | 9 (31.0) | 4 (44.4) | 0.389 |
Clinical and laboratory features | |||
Dysphagia | 18 (62.1) | 9 (100.0) | 0.038 |
Articular | 11 (37.9) | 5 (55.6) | 0.450 |
Pulmonary | 11 (37.9) | 3 (33.3) | 1.000 |
Creatine phosphokinase (U/L) | 5798 (2796–13,630) | 9000 (4484–12,472) | 0.457 |
Aldolase (U/L) | 36.1(18.7–42.3) | 28.2 (20.6–40.6) | 0.664 |
Autoantibodies | |||
Anti-Ro-52 | 11 (37.9) | 5 (55.6) | 0.450 |
Anti-Jo-1 | 9 (31.0) | 4 (44.4) | 0.689 |
Anti-Mi-2 | 4 (13.8) | 0 | – |
Anti-OJ | 0 | 0 | – |
Anti-EJ | 0 | 0 | – |
Anti-PL-7 | 0 | 0 | – |
Anti-PL-12 | 0 | 0 | – |
Antinuclear factor | 23 (73.9) | 8 (88.9) | 1.000 |
Pre-RTX infusion protocol | |||
Methylprednisolone + intravenous human immunoglobulin pulse therapy | 16 (55.2) | 7 (77.8) | 0.273 |